R-pharm
Clinical trials sponsored by R-pharm, explained in plain language.
-
New MS drug copycat aims to match ocrevus in early trial
Disease control OngoingThis Phase 1 trial compares a new drug called RPH-035 to the approved MS drug Ocrevus. The study involves 180 adults with relapsing-remitting or secondary progressive multiple sclerosis who have flare-ups. Researchers are checking if RPH-035 behaves similarly in the body and has …
Phase: PHASE1 • Sponsor: R-Pharm • Aim: Disease control
Last updated Jun 22, 2026 11:56 UTC
-
New hope for advanced breast cancer: could a biosimilar match the standard?
Disease control OngoingThis study tests whether a new drug called RPH-051 works as well as the approved drug Perjeta when both are given with standard chemotherapy and another targeted therapy for people with HER2-positive breast cancer that has spread or cannot be removed. About 246 participants will …
Phase: PHASE3 • Sponsor: R-Pharm • Aim: Disease control
Last updated Jun 18, 2026 11:48 UTC
-
New drug RPH-002 takes on erbitux in head and neck cancer showdown
Disease control OngoingThis study compares a new drug, RPH-002, to the standard drug Erbitux for people with advanced head and neck cancer that has spread or come back. Both drugs are given together with chemotherapy. The goal is to see if RPH-002 works as well as Erbitux at shrinking tumors. About 161…
Phase: PHASE3 • Sponsor: R-Pharm • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC